Those living with ALS are calling for disease-modifying treatments and faster access to those treatments. Research into the causes of ALS is accelerating but timelines involved in traditional drug development mean that for the majority of patients, treatments remain many years away. ALS remains underfunded and there is a relative lack of awareness of the condition with the public at large.
There is hope. In recent years there has been a shift in approach to the disease, thanks largely to patient lobbying groups and leading ALS charities. Green shoots of innovative practice are emerging, including the establishment of innovative trial platforms, higher levels of funding from the UK government, a lift in public awareness and the formation of a new Research Institute (MNDRI) and accelerator programmes.
As part of our Global Health portfolio of work, we have been looking into neurodegenerative diseases which gave rise to the Longitude Prize on Dementia and we are now expanding into ALS which we know could benefit from acceleration and profile-raising activities. Prizes work best to address underserved problems in need of transformational solutions and ALS is a prime example of that type of problem that we wish to champion and where we think we can make the biggest impact.
“Like thousands of other people living with ALS, I’ve experienced first-hand the shortcomings in available treatment. I believe our challenge prize can make a positive change to the landscape.” Tris Dyson, Challenge Works MD